Loading...
Market
How will the market react to the completion of Lundbeck's acquisition of Longboard Pharmaceuticals?
2
Resolution / Starting Odds
Lundbeck's stock rises over 5% • 25%
Lundbeck's stock falls over 5% • 25%
Longboard's stock remains stable • 25%
Other • 25%
Stock market data from financial platforms like Yahoo Finance or Bloomberg, financial news analysis
Story
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion at $60/Share, 77% Premium
Oct 14, 2024, 11:18 AM
Denmark's Lundbeck has announced its acquisition of Longboard Pharmaceuticals in a deal valued at $2.6 billion equity value. The acquisition, which will be executed at $60 per share in cash, represents a 77% premium to Longboard's volume-weighted average price (VWAP). The total transaction value is approximately $2.5 billion net of cash. The deal has been unanimously approved by the boards of both companies and is expected to close in the fourth quarter of 2024, pending regulatory approvals. This strategic acquisition aims to significantly enhance Lundbeck's neuroscience pipeline, particularly in the area of neuro-rare treatments. Centerview LLC acted as the financial advisor for the deal. Longboard's stock surged by over 50% in pre-market trading following the announcement. Longboard's Phase 3 asset for Dravet syndrome was a core interest for Lundbeck.
View original story
Similar markets
Positive • 25%
Neutral • 25%
Negative • 25%
Mixed • 25%
Increase > 10% • 25%
Increase 0-10% • 25%
Decrease 0-10% • 25%
Decrease > 10% • 25%
On time (by Q4 2024) • 25%
Delayed to Q1 2025 • 25%
Delayed to Q2 2025 or later • 25%
Deal Cancelled • 25%
Significant enhancement in neuroscience pipeline • 25%
Moderate enhancement • 25%
No significant change • 25%
Negative impact • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No changes • 25%
Minor changes • 25%
Major changes • 25%
Complete overhaul • 25%